[Efficacy of second-line treatment based on moxifloxacin triple therapy for Helicobacter pylori infection].
To evaluate the efficacy and tolerability of moxifloxacin-based triple therapy as an alternative second-line treatment for Helicobacter pylori (H. pylori) infection. A total of 109 patients, in whom the initial standard PPI triple therapy had failed to eradicate Hp infection, were included. Patients were randomized to one of the following 7-day treatment regimens: (1) rabeprazole 10 mg twice a day, moxifloxacin 400 mg/day and amoxicillin 1000 mg twice a day; and (2) rabeprazole 10 mg twice a day, bismuth salts 150 mg three times a day; clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day. The eradication rates and side-effect rates of these two regimens were compared. The eradication rates were 75.5% (40/53) and 83.3% (40/48) with moxifloxacin-based triple therapy, and 62.5% (35/56) and 71.4% (35/49) with bismuth-based quadruple therapy by intention-to-treat and per-protocol analyses (both P > 0.05) respectively. The 7-day moxifloxacin-based triple therapy has a high eradication rate with fewer side-effects. This regimen can be a safe and effective option as second-line treatment for H. pylori infection.